



# PRESS RELEASE

16 December 2008

## ENIGMA DIAGNOSTICS ANNOUNCES A SIGNED TERM SHEET FOR PATENT LICENSES WITH ROCHE MOLECULAR SYSTEMS, INC.

**Porton Down, UK & San Francisco, CA** – Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed a term sheet for two patent license agreements with Roche Molecular Systems, Inc. (RMS).

The licenses will provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and will allow Enigma to commercialize HybProbe diagnostic PCR tests for human and veterinary *in vitro* diagnostics on a worldwide basis, complementing Enigma's existing license under patents owned by Celera Diagnostics for real-time PCR thermal cyclers.

Enigma is currently developing a series of multiplexed, HybProbe assays for infectious diseases including chlamydia, influenza and MRSA. These tests will be combined with Enigma's revolutionary and fully automated real-time PCR system, the Enigma ML, to enable one-step molecular testing at point of care.

Financial terms were not disclosed.

**-ENDS-**

### Contacts

#### UK Contact:

**Enigma Diagnostics**

Deborah Cordingley

[deborah.cordingley@enigmadiagnostics.com](mailto:deborah.cordingley@enigmadiagnostics.com)

+44 1980 590131

#### US Contact:

**Richard Lewis Communications, Inc.**

212-827-0020

Megan Dubrowski - Media

[mdubrowski@rlcinc.com](mailto:mdubrowski@rlcinc.com)

Cecelia Heer - Investors

[cheer@rlcinc.com](mailto:cheer@rlcinc.com)



# PRESS RELEASE

## About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK-based company specializing in developing the next generation of rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralized and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit [www.enigmadiagnostics.com](http://www.enigmadiagnostics.com)